 Initial studies in the USA were conducted in collaboration with Unimed Pharmaceuticals, Inc. (Marietta, GA) and focused on development of the drug for treatment of cryptosporidiosis in AIDS.Controlled trials began shortly after the advent of effective anti-retroviral therapies.The trials were abandoned due to poor enrollment and the FDA rejected an application based on uncontrolled studies.